Miramar Labs, Inc.® Reports Fourth Quarter and Full

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
87
Miramar Labs, Inc.® Reports Fourth Quarter and Full Year 2016 Financial Results

Highlights:

  • 2016 revenue of $20.4 million, up 19% year-over-year
  • Strong sales in North America with year-over-year growth of 38%
  • Gross margin expands to 55% in 2016, up from 52% in the prior year

SANTA CLARA, Calif., March 16, 2017 (GLOBE NEWSWIRE) -- Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today financial results for fourth quarter and full year ended December 31, 2016.

Michael Kleine, President and Chief Executive Officer of Miramar Labs, said, "We continued to achieve very strong momentum in our North America business, which grew 38% in 2016, driven by our efforts to increase awareness and adoption of our technology. We are also benefiting from the indication expansion for the miraDry ® system, which now provides three distinct benefits to both physicians and patients with its ability to reduce axillary sweat, odor and hair. This unique value proposition for our customers and consumers, is a core driver of expanding our business and delivering on our growth objectives."

In 2016, Miramar expanded its approved indications for the miraDry system and received FDA 510(k) clearance to market for the reduction of odor. The miraDry system is now FDA cleared with indications for sweat, odor and hair reduction, expanding the utility of the system.  Recognition of these advancements of the application of the proprietary miraWave technology was recognized with Aesthetics Everything naming Miramar Labs as one of  ”The Top Aesthetics Companies in 2016".

Mr. Kleine concluded, "We are excited to continue building consumer awareness and further accelerating sales with the addition of celebrity spokesperson and miraDry patient Antonio Sabato Jr. This is complementary to our strategy to increase our focus on social media, where we have seen a strong interest reflecting the early impact of our miraDry is Confidence campaign. In addition, our marketing efforts are building awareness of the miraDry treatment among potential customers and patients, highlighting its effectiveness and high patient satisfaction."

Financial Results

Total revenue in the fourth quarter of 2016 was $4.4 million, a 18% decrease compared to $5.4 million in the fourth quarter of 2015. The year-over-year decline was primarily due to the timing of Asia console sales, which were received in earlier quarters in 2016 as compared to 2015.  For the year ended December 31, 2016, revenue totaled $20.4 million, a 19% increase compared to $17.2 million for the year ended December 31, 2015. This revenue increase reflects strong sales of both capital systems and consumables. As mentioned above, North America growth was 38% for the year, with strong performance in capital systems and consumables. In Asia, revenue grew 6% for the year, driven by very strong capital system sales growth of 45%, offset by disappointing consumable sales associated with the transition of a distributor in a key market. In Europe and the Middle East, sales grew 10% driven by strong consumable sales with growth of 69%, offset by lower console sales due to the termination and transition of key distributors.

Total gross margin in the fourth quarter of 2016 was $2.5 million, or 56% of revenue, compared to $2.9 million, or 53% of revenue, in the same period in 2015.  Gross margin for the year ended December 31, 2016 was $11.3 million, or 55% of revenue, compared to $8.9 million, or 52% of revenue, for the same period in 2015. The increase in gross margin is primarily attributable to a higher percentage of sales in North America and Asia-Pacific, where Miramar Labs has higher selling prices, in addition to lower cost of revenue due to higher production volumes and favorable labor efficiencies, as compared to the same periods in 2015.

Total operating expenses for the three months and year ended December 31, 2016, were $5.7 million and $22.9 million, compared to $5.4 million and $22.2 million for the same periods in 2015.  For both the three months and year ended December 31, 2016, higher sales and general and administrative expenses were offset by lower research and development expense for the same periods.

Net loss for the three months and year ended December 31, 2016 was $3.4 million, or $(0.37) per share, and $20.4 million or $(3.80) per share, compared to a net loss of $2.8 million, or $(6.89) per share, and $14.5 million, or $(37.33) per share for the three months and year ended December 31, 2015.  In the second quarter, the company recorded a one-time non-cash charge of $8.1 million for the loss on the conversion of debt associated with the merger.  The non-GAAP loss for the three months and year ended December 31, 2016 was $3.4 million, or $(0.37) per share, and $12.4 million, or $(2.30) per share, compared to a non-GAAP loss of $2.7 million and $14.5 million for the three months and year ended December 31, 2015.

Miramar Labs had total cash and cash equivalents of $2.2 million at December 31, 2016.

Use of Non-GAAP Financial Measure: Miramar Labs has supplemented its GAAP net loss with a non-GAAP measure of net loss.  Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of Miramar Labs, facilitates a more meaningful comparison of results for current periods with previous operating results, and assists management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts.  A reconciliation of GAAP net loss to non-GAAP net loss in the most directly comparable GAAP measure is provided in the schedule below.  GAAP net loss is the most directly comparable measure to non-GAAP net loss.

There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with Miramar Lab's consolidated financial statements prepared in accordance with GAAP and the reconciliation of the non-GAAP financial measure provided in the schedule below.

About Miramar Labs: Miramar Labs, Inc. is a global medical device company dedicated to bringing innovative and clinically proven applications to treat unmet needs in the aesthetic marketplace. Supported by rigorous clinical research, Miramar Labs is focused on addressing aesthetic medical conditions for which there are significant unmet clinical needs. The company’s first priority is the treatment of bothersome underarm sweat, an issue that hundreds of millions of people deal with daily. The miraDry procedure has an established safety and efficacy profile with over 80,000 patients treated worldwide. Physicians and patients are encouraged to visit  www.miramarlabs.com or www.miradry.com  for additional information.

Forward Looking Statements: This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to expansion opportunities, revenue generation, anticipated uses of proceeds from the private placement and business and product development plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue our business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the miraDry system, competition in the industry in which we operate and overall market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should review all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC, which are available at www.sec.gov .

 
MIRAMAR LABS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
 
  Three months ended December 31,   Year ended December 31,
  2016     2015     2016     2015  
Revenue $ 4,411,195     $ 5,377,191     $ 20,446,533     $ 17,199,511  
Cost of revenue 1,927,565     2,511,751     9,138,675     8,257,048  
Gross margin 2,483,630     2,865,440     11,307,858     8,942,463  
Operating expenses:              
Research and development 756,540     1,032,760     3,319,021     4,974,120  
Selling and marketing 3,575,397     2,776,914     13,550,645     11,757,734  
General and administrative 1,319,398     1,561,094     6,036,389     5,468,916  
Total operating expenses 5,651,335     5,370,768     22,906,055     22,200,770  
Loss from operations (3,167,705 )   (2,505,328 )   (11,598,197 )   (13,258,307 )
Interest income 1,826     930     9,590     5,931  
Interest expense (283,940 )   (270,917 )   (1,232,602 )   (1,295,930 )
Loss on debt conversion —     —     (8,062,001 )   —  
Other income, net 18,883     (25,324 )   457,031     62,780  
Net loss before provision for income taxes (3,430,936 )   (2,800,639 )   (20,426,179 )   (14,485,526 )
Provision for income taxes —     —     (9,308 )   (8,722 )
Net and comprehensive loss (3,430,936 )   (2,800,639 )   (20,435,487 )   (14,494,248 )
Accretion of redeemable convertible preferred stock —     60,000     —     (3,117 )
Net loss attributable to common stockholders $ (3,430,936 )   $ (2,740,639 )   $ (20,435,487 )   $ (14,497,365 )
Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic and diluted 9,366,217     397,504     5,379,421     388,379  
Net loss per share attributable to common stockholders, basic and diluted $ (0.37 )   $ (6.89 )   $ (3.80 )   $ (37.33 )
Non GAAP              
GAAP net loss attributable to common stockholders $ (3,430,936 )   $ (2,740,639 )   $ (20,435,487 )   $ (14,497,365 )
Loss on debt conversion —     —     (8,062,001 )   —  
Non GAAP net loss attributable to common stockholders $ (3,430,936 )   $ (2,740,639 )   $ (12,373,486 )   $ (14,497,365 )
Weighted-average common shares used in computing net loss per share attributable to common stockholders, basic and diluted 9,366,217     397,504     5,379,421     388,379  
Non GAAP net loss per share attributable to common stockholders, basic and diluted $ (0.37 )   $ (6.89 )   $ (2.30 )   $ (37.33 )
MIRAMAR LABS, INC.
Condensed Consolidated Balance Sheets
 
  December 31,  2016   December 31,  2015
  (Audited)   (Audited)
ASSETS      
Current assets:      
Cash and cash equivalents $ 2,203,639     $ 2,642,509  
Accounts receivable, net 3,159,423     2,683,053  
Inventories 6,649,840     4,791,741  
Prepaid expenses and other current assets 341,048     290,481  
Total current assets 12,353,950     10,407,784  
Property and equipment, net 714,797     1,211,129  
Restricted cash 295,067     295,067  
Other non-current assets 13,976     11,860  
TOTAL ASSETS $ 13,377,790     $ 11,925,840  
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’ DEFICIT      
Current liabilities:      
Notes payable, net of discount $ 9,916,626     $ 10,829,375  
Accounts payable 1,582,145     1,288,107  
Accrued and other current liabilities 4,567,076     3,572,441  
Deferred revenue 182,160     739,786  
Total current liabilities 16,248,007     16,429,709  
Warrant liability 7,342     499,616  
Deferred rent, non-current 77,309     112,065  
Capital lease payable, non-current —     16,865  
TOTAL LIABILITIES 16,332,658     17,058,255  
Commitments and contingencies      
Redeemable convertible preferred stock, $.001 par value - 40,000,000 shares authorized and 2,826,981 shares issued and outstanding at December 31, 2015 (Liquidation preference of $61,179,942).  No shares authorized or outstanding at December 31, 2016 —     61,179,942  
Stockholders’ deficit:      
Blank check preferred stock, $0.001 par value - 5,000,000 shares authorized. No shares issued and outstanding at December 31, 2016 and 2015. —     —  
Series A convertible preferred stock, $0.001 par value - 2,100,000 shares authorized and 147,864 shares issued and outstanding at December 31, 2015 (Liquidation preference of $2,000,000). No shares authorized or outstanding at December 31, 2016. —     148  
Series B convertible preferred stock, $0.001 par value - 9,000,000 shares authorized and 589,784 shares issued and outstanding at December 31, 2015 (Liquidation preference of $14,359,244). No shares authorized or outstanding at December 31, 2016 —     590  
Common stock, $0.001 par value - 100,000,000 and 105,500,000 shares authorized and 9,334,857 and 398,540 shares issued and outstanding at December 31, 2016 and 2015 9,335     399  
Additional paid-in capital 110,918,412     27,133,634  
Accumulated deficit (113,882,615 )   (93,447,128 )
TOTAL STOCKHOLDERS’ DEFICIT (2,954,868 )   (66,312,357 )
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 13,377,790     $ 11,925,840  
               

 

Contact: Investors: Brigid Makes Sr. Vice President & Chief Financial Officer Phone: 408.579.8700 Email: investors@miramarlabs.com Media/Other: Robert Ellis Vice President of Global Marketing Phone: 408-579-8706 Email: info@miramarlabs.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 96

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 84

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 421

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 80

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 103

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 85

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 59

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 59

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Fly Play hf. Amid Takeover Talks

Updated Category News Views 224

Understanding the Recent Developments at Fly Play hf. Fly Play hf. is currently navigating through a significant phase in its operational journey. Amid potential takeover discussions, stakeholders are keenly interested in how such a move could reshape the airline's direction. As the aviation industry continues to evolve, Fly Play's adaptability and innovative strategies...

Continue Reading
AvePoint Aims for Dual Listing at Singapore Exchange

Updated Category News Views 275

AvePoint's Ambitious Step Towards Dual Listing AvePoint (Nasdaq: AVPT), renowned as a leader in data security, governance, and resilience, is taking a significant step forward by submitting an application to list its shares on the Singapore Exchange Securities Trading Limited (SGX-ST). This application is set against the backdrop of its existing presence on the Nasdaq...

Continue Reading
Kris Kehl Joins Planet Home Lending to Enhance Services

Updated Category News Views 140

Kris Kehl Joins Planet Home Lending Team Planet Home Lending, a prominent national mortgage lender, is excited to announce the addition of Kris Kehl as a Senior Mortgage Loan Officer in California. With over 22 years of extensive experience in the mortgage industry, Kehl brings a relationship-first approach that prioritizes accessibility, clear communication, and...

Continue Reading
The S&P 500: Understanding Future Market Return Challenges

Updated Category News Views 647

Understanding Future Returns for the S&P 500 Recently, there’s been a surge of interest regarding predictions for future returns of the S&P 500. With insights from financial giants like J.P. Morgan and Goldman Sachs indicating a significantly lower return forecast for the coming decade, it’s essential to delve deeper into these evaluations. The consistent message has...

Continue Reading
Investors Can Seize Winds of Change with enCore Energy

Updated Category News Views 183

Understanding the Opportunity with enCore Energy Corp. Investors are currently presented with a significant opportunity to engage in the ongoing developments at enCore Energy Corp. (NASDAQ: EU). The global landscape is rapidly changing, especially in the energy sector, and enCore is no exception. A class action has been filed on behalf of shareholders who purchased...

Continue Reading